US 11,299,465 B2Granted

Carboxylic acid compounds

AssigneeSumitomo Dainippon Pharma Co., Ltd.

InventorsSeiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

Claims18

Dependent claims

A method of treating cancer in a subject in need thereof comprising:

administering to said subject a therapeutically effective amount of at least one compound selected from a group consisting of:
2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2-difluoroethyl)amino)acetic acid,
2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2,2-triflooroethyl)amino)acetic acid,
(S)-2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2-diflooroethyl)amio)acetic acid, and
(S)-2-((4-((2-amino-4-(1-hydroxyhexan-3-ylamino)-6-methylpyrimidin-5-yl)methyl)-3-methoxybenzyl)(2,2,2-trifluoroethyl)amino)acetic acid, and
pharmaceutically acceptable salts of any on the foregoing,
wherein the cancer is chosen from bladder cancer, head and neck cancer, prostate cancer, breast cancer, lung cancer, renal carcinoma, ovarian cancer, colon carcinoma, skin cancer, osteosarcoma, and a lymphoproliferative tumor.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/736,660Filed 7 Jan 2020 · continuation
Priority: 18 May 2012
Published: US 2020/0317623 A18 Oct 2020
Granted: 12 Apr 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification26 codes

C07D 239/48
Two or more oxygen, sulphur or nitrogen atoms: two nitrogen atoms
A61P 11/00
Drugs for disorders of the respiratory system
A61P 11/02
Drugs for disorders of the respiratory system: nasal agents, e.g. decongestants
A61P 11/06
Drugs for disorders of the respiratory system: antiasthmatics

Family

Application61/648,816Us provisional application · filed 18 May 2012
Application61/806,158Us provisional application · filed 28 Mar 2013
PCT/JP2013/064420Parent of this continuation · filed 17 May 2013
Application15/152,497Parent of this continuation · filed 11 May 2016
US 9,376,398 B2Parent of this continuation · filed 28 Jun 2016
Application16/167,974Parent of this continuation · filed 23 Oct 2018
US 10,150,743 B2Parent of this continuation · filed 11 Dec 2018
US 2020/0317623 A1Pre-grant publication · published 8 Oct 2020
US 10,562,861 B2Parent of this continuation
Application14/401,366Parent of this continuation
US 2015/0099770 A1Published application
US 2016/0251319 A1Published application
US 2019/0119220 A1Published application
US 11,299,465 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key